Department of Clinical and Molecular Biomedicine, Division of Infectious Diseases, University of Catania, ARNAS Garibaldi Nesima, Catania, Italy.
Eur Rev Med Pharmacol Sci. 2013 Aug;17(16):2218-24.
Across Europe, more than one third of patients are diagnosed with HIV infection late. Late presentation for care has been associated with higher risk of clinical progression and mortality. In the present study, we evaluated the prevalence, epidemiological characteristics and survival probability of patients with late and very late presentation, newly diagnosed with HIV infection in Catania, Italy, from 1985 to 2010.
According to the European Consensus definition, Late Presenters (LP) were defined as subjects presenting for care with a CD4+ T-cell count below 350 cells/µl or with an AIDS-defining event, regardless of CD4+ T-cell count; patients with advanced HIV disease (Very Late Presenters) (VLP) were those presenting with a CD4+ T-cell count below 200 cells/µl or with an AIDS-defining event, regardless of CD4+ T-cell count.
620 patients were included in the study. 345 (55.6%) subjects were LP, 35% of them were asymptomatic; 246 (39.7%) were VLP. In univariate analysis, late presentation was related to age (p < 0.001), to heterosexual exposure to HIV infection (70% of heterosexual subjects were LP) (p < 0.005) and to being diagnosed during the calendar period from 1991 to 2000 (p < 0.001). Very late presentation was related to age (p < 0.001), male sex (p < 0.01), heterosexual risk (p < 0.001) and to being diagnosed during the calendar period from 1991 to 2000 (p < 0.001). In multivariate analysis, age (p < 0.0001), being older than 50 years old (p = 0.02), years of diagnosis 1991-1995 (p < 0.005) and 1996-2000 (p < 0.05) in the subgroup of late presenters and age (p < 0.0001), being older than 50 years old (p < 0.005), male sex (p < 0.0001), years of diagnosis 1991-1995 (p < 0.05) and 1996-2000 (p < 0.005) in the subgroup of very late presenters maintained statistical significance. The survival probability within LP and VLP group was statistically lower than no LP/VLP (log rank test p < 0.0005 and p < 0.0001, respectively). For both LP (p < 0.002) and VLP (p < 0.0001), survival probability was significantly lower in the pre-HAART era, in comparison with the period of mono/dual therapy and the HAART era.
More than fifty percent of patients in our setting were diagnosed late with HIV infection and, consequently, treated late. Late and very late presentation were associated with lower survival probability. The implementation of strategies focused on targeted prevention efforts and HIV testing programs appears fundamental to diagnose and treat HIV infection as early as possible.
在整个欧洲,超过三分之一的患者被诊断为 HIV 感染晚期。晚期就诊与更高的临床进展和死亡率风险相关。在本研究中,我们评估了意大利卡塔尼亚从 1985 年至 2010 年新诊断为 HIV 感染的晚期和极晚期患者的流行率、流行病学特征和生存概率。
根据欧洲共识定义,晚期患者(LP)定义为就诊时 CD4+ T 细胞计数低于 350 个/µl 或出现 AIDS 定义性事件的患者,无论 CD4+ T 细胞计数如何;晚期 HIV 疾病患者(VLP)定义为就诊时 CD4+ T 细胞计数低于 200 个/µl 或出现 AIDS 定义性事件的患者,无论 CD4+ T 细胞计数如何。
共纳入 620 例患者。345 例(55.6%)患者为 LP,其中 35%为无症状患者;246 例(39.7%)为 VLP。单因素分析显示,晚期就诊与年龄(p < 0.001)、异性恋感染 HIV(70%的异性恋患者为 LP)(p < 0.005)以及在 1991 年至 2000 年期间诊断有关(p < 0.001)。极晚期就诊与年龄(p < 0.001)、男性(p < 0.01)、异性恋风险(p < 0.001)以及在 1991 年至 2000 年期间诊断有关(p < 0.001)。多因素分析显示,年龄(p < 0.0001)、年龄大于 50 岁(p = 0.02)、1991-1995 年(p < 0.005)和 1996-2000 年(p < 0.05)诊断年限在晚期患者亚组中,年龄(p < 0.0001)、年龄大于 50 岁(p < 0.005)、男性(p < 0.0001)、1991-1995 年(p < 0.05)和 1996-2000 年(p < 0.005)诊断年限在极晚期患者亚组中保持统计学意义。LP 和 VLP 组的生存概率明显低于无 LP/VLP 组(对数秩检验 p < 0.0005 和 p < 0.0001)。对于 LP(p < 0.002)和 VLP(p < 0.0001),与单药/联合治疗和 HAART 时代相比,HAART 时代之前的生存率明显较低。
在我们的研究环境中,超过一半的患者被诊断为 HIV 感染晚期,因此接受晚期治疗。晚期和极晚期就诊与较低的生存率相关。实施以有针对性的预防措施和 HIV 检测计划为重点的策略似乎对于尽早诊断和治疗 HIV 感染至关重要。